EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Infusion Therapies in the Treatment of Parkinson’s Disease

Teus van Laar, K Ray Chaudhuri, Angelo Antonini, Tove Henriksen, Maja Trošt

Journal of Parkinson’s Disease · 16.06.2023 · 13 (5) · 641-657

DOI: 10.3233/jpd-225112 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 12.06.2023. Verfasst von Teus van Laar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral levodopa is the gold-standard therapy for treating Parkinson’s disease (PD) but after a few years of treatment the therapeutic window narrows, and patients often experience various treatment-related complications. Patients in this advanced PD stage may benefit from alternative therapy, such as continuous intrajejunal delivery of levodopa-carbidopa intestinal gel (LCIG; or carbidopa-levodopa enteral suspension), continuous intrajejunal delivery of levodopa-carbidopa-entacapone intestinal gel, or continuous subcutaneous apomorphine infusion. Consideration and initiation of infusion therapies in advanced PD are suggested before the onset of major disability. The present review summarizes clinical evidence for infusion therapy in advanced PD management, discusses available screening tools for advanced PD, and provides considerations around optimal use of infusion therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansLevodopaCarbidopaAntiparkinson AgentsGelsDrug Combinations

Stichwörter der Autor:innen

Continuous subcutaneous infusionParkinson’s diseaseapomorphinecarbidopaimplantable infusion pumpslevodopa drug combination

Substanzen

LevodopaCarbidopaAntiparkinson AgentsGelsDrug Combinations

Autor:innen und Institutionen

  • Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Psychology & Neuroscience, King's College Institute of Psychiatry, London, UK.
  • Parkinson and Movement Disorders Unit, Study Center on Neurodegeneration (CESNE), Department of Neuroscience, Padua University, Padua, Italy.
  • Department of Neurology, Movement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark.
  • Department of Neurology, University Medical Centre Ljubljana, Slovenia, Faculty of Medicine, University of Ljubljana, Slovenia.

Zitieren

APA

van Laar, T., Chaudhuri, K. R., Antonini, A., Henriksen, T., & Trošt, M. (2023). Infusion Therapies in the Treatment of Parkinson’s Disease. Journal of Parkinson’s Disease, 13(5), 641-657. https://doi.org/10.3233/jpd-225112

Vancouver

van Laar T, Chaudhuri KR, Antonini A, Henriksen T, Trošt M. Infusion Therapies in the Treatment of Parkinson’s Disease. Journal of Parkinson’s Disease. 2023;13(5):641-657. doi:10.3233/jpd-225112

BibTeX
@article{vanLaar2023,
  author = {van Laar, Teus and Chaudhuri, K Ray and Antonini, Angelo and Henriksen, Tove and Trošt, Maja},
  title = {Infusion Therapies in the Treatment of Parkinson’s Disease},
  journal = {Journal of Parkinson’s Disease},
  year = {2023},
  volume = {13},
  number = {5},
  pages = {641--657},
  doi = {10.3233/jpd-225112}
}
Kostenlos starten →